INS 1007Alternative Names: AZD 7986; INS1007
Latest Information Update: 06 Oct 2016
At a glance
- Originator AstraZeneca
- Class Anti-inflammatories; Antibronchitics; Small molecules
- Mechanism of Action Dipeptidyl peptidase I inhibitors; Leucocyte elastase modulators; Neutrophil modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Chronic obstructive pulmonary disease